Funder: National Institutes of Health
Due Dates: April 10, 2025 (Application) | August 11, 2025 (Application) | March 11, 2025 & July 12, 2025 (Letters of Intent) | August 12, 2025 (Expiration)
Funding Amounts: Up to $5 million/year (direct costs) for up to 3 years; cooperative agreement (U01); NIH anticipates ~5 awards/year.
Summary: Large, short-term grants to accelerate preclinical and clinical research advancing medications for substance use disorders toward FDA approval.
Key Information: Clinical trial proposals are allowed but not required; close NIDA involvement and milestone-driven progress are expected.